title: Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study.
abstract: OBJECTIVE
  To compare the efficacy and safety of a biweekly CHOP regimen consisting of cyclophosphamide (CPA), doxorubicin (DOX), vincristine (VCR), and prednisolone (PSL) and those of a biweekly THP-COP regimen containing pirarubicin (THP), an anthracyclin with less cardiotoxicity than DOX.
  
  
  METHODS
  A prospective, randomized phase II study with 80 patients (40 receiving CHOP or THP-COP) less than 70 years of age with previously untreated aggressive non-Hodgkin's lymphoma (NHL). The regimens consisted of DOX or THP 50 mg/m2, CPA 750 mg/m2, VCR 1.4 mg/m2, and PSL 100 mg/body administered for 5 days every 2 weeks for eight cycles.
  
  
  RESULTS
  No significant differences in known prognostic factors were found between the two groups. Complete remission rate was 72.5% (72.5% for CHOP, 72.5% for THP-COP). The 5-year overall survival rate was 49.2% (43.7% for CHOP, 54.0% for THP-COP). When the patients were divided into groups with favorable or poor prognostic factors according to the International Prognostic Index, survival of the former group (L/LI) was superior to that of the later group (HI/H), regardless of chemotherapy regimen ( P < 0.001). Although grade 3 cardiotoxicity occurred in one patient in the CHOP group, no fatal toxic reactions occurred in either group. The THP-COP produced results equivalent to those of CHOP regarding efficacy and safety in aggressive NHL patients less than 70 years of age.
  
  
  CONCLUSIONS
  Although both regimens effectively treated those patients with favorable prognostic factors, neither was satisfactory for treating those with poor prognostic factors.
authors.affiliation: First Department of Internal Medicine, Gifu University School of Medicine, 40 Tsukasa-machi, 500-8705, Japan.
authors.forename: Hisashi
authors.initials: H
authors.lastname: Tsurumi
authors.forename: Toshiki
authors.initials: T
authors.lastname: Yamada
authors.forename: Michio
authors.initials: M
authors.lastname: Sawada
authors.forename: Senji
authors.initials: S
authors.lastname: Kasahara
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Kanemura
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Kojima
authors.forename: Kenji
authors.initials: K
authors.lastname: Fukuno
authors.forename: Takeshi
authors.initials: T
authors.lastname: Hara
authors.forename: Masanao
authors.initials: M
authors.lastname: Saio
authors.forename: Takeshi
authors.initials: T
authors.lastname: Takahashi
authors.forename: Masami
authors.initials: M
authors.lastname: Oyama
authors.forename: Keiya
authors.initials: K
authors.lastname: Ozawa
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Takami
authors.forename: Hisataka
authors.initials: H
authors.lastname: Moriwaki
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D011446:Prospective Studies; D012307:Risk Factors; D016019:Survival Analysis; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D011241:Prednisone